IM
IM
IM
0.1 Results
Factor | Detalis | Total |
N= | 243 | |
DG | NASH | 60 (24.7%) |
ASH | 89 (36.6%) | |
VIRAL | 94 (38.7%) | |
Gender | F | 44 (18.1%) |
M | 199 (81.9%) | |
Age | μ ±DS | 66.04 ±9.01 |
M (min:max) | 66.5 (45.2:86.1) | |
Year_of_diagnosis | 2008 | 3 (1.2%) |
2009 | 8 (3.3%) | |
2010 | 21 (8.6%) | |
2011 | 25 (10.3%) | |
2012 | 21 (8.6%) | |
2013 | 16 (6.6%) | |
2014 | 20 (8.2%) | |
2015 | 23 (9.5%) | |
2016 | 31 (12.8%) | |
2017 | 25 (10.3%) | |
2018 | 27 (11.1%) | |
2019 | 23 (9.5%) | |
Survival | μ ±DS | 29.03 ±27.1 |
M (min:max) | 20.5 (0:114) | |
MRI_diagnosis | 0 | 159 (65.7%) |
1 | 83 (34.3%) | |
CT_Diagnosis | 0 | 101 (41.7%) |
1 | 141 (58.3%) | |
US_Diagnosis | 0 | 160 (66.1%) |
1 | 82 (33.9%) | |
HCC_Screening_18months_before | 0 | 134 (55.1%) |
1 | 109 (44.9%) | |
US_Screening | 0 | 171 (70.4%) |
1 | 72 (29.6%) | |
MRI_Screening | 0 | 221 (90.9%) |
1 | 22 (9.1%) | |
CT_Screening | 0 | 197 (81.1%) |
1 | 46 (18.9%) | |
ASH | 0 | 154 (63.4%) |
1 | 89 (36.6%) | |
NASH | 0 | 183 (75.3%) |
1 | 60 (24.7%) | |
Cirrhosis | 204 (84.0%) | |
HCV | 0 | 176 (72.4%) |
1 | 67 (27.6%) | |
HBc | 0 | 216 (88.9%) |
1 | 27 (11.1%) | |
Diagnosis | 1 | 60 (24.7%) |
2 | 89 (36.6%) | |
3 | 94 (38.7%) | |
Diabetes | 0 | 165 (67.9%) |
1 | 78 (32.1%) | |
Hipertension | 0 | 121 (51.9%) |
1 | 112 (48.1%) | |
Hiperlipidemia | 0 | 200 (85.8%) |
1 | 33 (14.2%) | |
Smoking | 0 | 130 (55.3%) |
1 | 105 (44.7%) | |
Alcohol_Consume | 0 | 170 (72.3%) |
1 | 65 (27.7%) | |
BMI | μ ±DS | 27.38 ±5.1 |
M (min:max) | 26.44 (16.02:46.02) | |
Encephalopathy (according to Child-Pugh score) | 1 | 221 (94.4%) |
2 | 12 (5.1%) | |
3 | 1 (0.4%) | |
Ascites (according to Child-Pugh score) | 1 | 191 (82.0%) |
2 | 29 (12.4%) | |
3 | 13 (5.6%) | |
Bilirubin total (µmol/L) | μ ±DS | 22.17 ±25.1 |
M (min:max) | 16 (3:286) | |
INR | μ ±DS | 1.15 ±0.184 |
M (min:max) | 1.11 (0.8:2.07) | |
Albumin (g/L) | μ ±DS | 33.20 ±5.69 |
M (min:max) | 34 (20:44) | |
CHILD | 1 | 152 (65.8%) |
2 | 67 (29.0%) | |
3 | 12 (5.2%) | |
BCLC | 0 | 18 (7.4%) |
1 | 106 (43.6%) | |
2 | 57 (23.5%) | |
3 | 48 (19.8%) | |
4 | 14 (5.8%) | |
Resection | 0 | 191 (78.9%) |
1 | 51 (21.1%) | |
Transplant | 0 | 214 (88.4%) |
1 | 28 (11.6%) | |
TACE | 0 | 209 (86.4%) |
1 | 33 (13.6%) | |
TAE | 0 | 228 (94.2%) |
1 | 14 (5.8%) | |
RFA | 0 | 233 (96.7%) |
1 | 8 (3.3%) | |
MWA | 0 | 200 (82.6%) |
1 | 42 (17.4%) | |
SIRT | 0 | 235 (97.1%) |
1 | 7 (2.9%) | |
Sistemic_therapy | 0 | 201 (83.1%) |
1 | 41 (16.9%) | |
Curative_treatment | 0 | 151 (62.4%) |
1 | 91 (37.6%) | |
Loco_regional_therapies | 0 | 192 (79.3%) |
1 | 50 (20.7%) | |
No_treatment | 0 | 208 (86.0%) |
1 | 34 (14.0%) | |
Treatment | Curative | 91 (37.6%) |
Transplant | 27 (11.2%) | |
Loco-regional | 50 (20.7%) | |
Sistemic | 40 (16.5%) | |
No treatment | 34 (14.0%) | |
Performance Status | 0 | 141 (59.5%) |
1 | 65 (27.4%) | |
2 | 20 (8.4%) | |
3 | 8 (3.4%) | |
4 | 3 (1.3%) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); | ||
Factor | Detalis | NASH | ASH | VIRAL | Total | Statistics |
DG | 60 (24.7%) | 89 (36.6%) | 94 (38.7%) | 243 | ||
Gender | F | 10 (16.7%) | 11 (12.4%) | 23 (24.5%) | 44 (18.1%) | V=0.14 (p=0.099) |
M | 50 (83.3%) | 78 (87.6%) | 71 (75.5%) | 199 (81.9%) | ||
Age | μ ±DS | 70.24 ±7.04 | 66.70 ±8.69 | 62.74 ±9.25 | 66.04 ±9.01 | Kruskal-Wallis: p<0.001 |
M (min:max) | 70.45 (50.9:86.1) | 66.7 (45.2:86) | 60.7 (45.5:83.9) | 66.5 (45.2:86.1) | ||
Year_of_diagnosis | 2008 | 1 (1.7%) | 1 (1.1%) | 1 (1.1%) | 3 (1.2%) | V=0.21 (p=0.554) |
2009 | 2 (3.3%) | 4 (4.5%) | 2 (2.1%) | 8 (3.3%) | ||
2010 | 5 (8.3%) | 8 (9.0%) | 8 (8.5%) | 21 (8.6%) | ||
2011 | 3 (5.0%) | 6 (6.7%) | 16 (17.0%) | 25 (10.3%) | ||
2012 | 6 (10.0%) | 7 (7.9%) | 8 (8.5%) | 21 (8.6%) | ||
2013 | 3 (5.0%) | 7 (7.9%) | 6 (6.4%) | 16 (6.6%) | ||
2014 | 5 (8.3%) | 5 (5.6%) | 10 (10.6%) | 20 (8.2%) | ||
2015 | 6 (10.0%) | 7 (7.9%) | 10 (10.6%) | 23 (9.5%) | ||
2016 | 7 (11.7%) | 11 (12.4%) | 13 (13.8%) | 31 (12.8%) | ||
2017 | 7 (11.7%) | 8 (9.0%) | 10 (10.6%) | 25 (10.3%) | ||
2018 | 7 (11.7%) | 12 (13.5%) | 8 (8.5%) | 27 (11.1%) | ||
2019 | 8 (13.3%) | 13 (14.6%) | 2 (2.1%) | 23 (9.5%) | ||
Survival | μ ±DS | 25.05 ±26.0 | 29.65 ±29.6 | 31.13 ±25.3 | 29.03 ±27.1 | Kruskal-Wallis: p=0.178 |
M (min:max) | 15 (0:110) | 20 (0:114) | 23 (0:112) | 20.5 (0:114) | ||
MRI_diagnosis | 0 | 40 (66.7%) | 61 (68.5%) | 58 (62.4%) | 159 (65.7%) | V=0.06 (p=0.670) |
1 | 20 (33.3%) | 28 (31.5%) | 35 (37.6%) | 83 (34.3%) | ||
CT_Diagnosis | 0 | 24 (40.0%) | 35 (39.3%) | 42 (45.2%) | 101 (41.7%) | V=0.06 (p=0.692) |
1 | 36 (60.0%) | 54 (60.7%) | 51 (54.8%) | 141 (58.3%) | ||
US_Diagnosis | 0 | 38 (63.3%) | 60 (67.4%) | 62 (66.7%) | 160 (66.1%) | V=0.03 (p=0.866) |
1 | 22 (36.7%) | 29 (32.6%) | 31 (33.3%) | 82 (33.9%) | ||
HCC_Screening_18months_before | 0 | 33 (55.0%) | 58 (65.2%) | 43 (45.7%) | 134 (55.1%) | V=0.17 (p=0.031) |
1 | 27 (45.0%) | 31 (34.8%) | 51 (54.3%) | 109 (44.9%) | ||
US_Screening | 0 | 41 (68.3%) | 70 (78.7%) | 60 (63.8%) | 171 (70.4%) | V=0.14 (p=0.083) |
1 | 19 (31.7%) | 19 (21.3%) | 34 (36.2%) | 72 (29.6%) | ||
MRI_Screening | 0 | 54 (90.0%) | 80 (89.9%) | 87 (92.6%) | 221 (90.9%) | V=0.04 (p=0.786) |
1 | 6 (10.0%) | 9 (10.1%) | 7 (7.4%) | 22 (9.1%) | ||
CT_Screening | 0 | 50 (83.3%) | 71 (79.8%) | 76 (80.9%) | 197 (81.1%) | V=0.04 (p=0.861) |
1 | 10 (16.7%) | 18 (20.2%) | 18 (19.1%) | 46 (18.9%) | ||
ASH | 0 | 60 (100%) | 0 | 94 (100%) | 154 (63.4%) | V=1.00 (p<0.001) |
1 | 0 | 89 (100%) | 0 | 89 (36.6%) | ||
NASH | 0 | 0 | 89 (100%) | 94 (100%) | 183 (75.3%) | V=1.00 (p<0.001) |
1 | 60 (100%) | 0 | 0 | 60 (24.7%) | ||
Cirrhosis | 47 (78.3%) | 80 (89.9%) | 77 (81.9%) | 204 (84.0%) | V=0.13 (p=0.134) | |
HCV | 0 | 60 (100%) | 89 (100%) | 27 (28.7%) | 176 (72.4%) | V=0.78 (p<0.001) |
1 | 0 | 0 | 67 (71.3%) | 67 (27.6%) | ||
HBc | 0 | 60 (100%) | 89 (100%) | 67 (71.3%) | 216 (88.9%) | V=0.45 (p<0.001) |
1 | 0 | 0 | 27 (28.7%) | 27 (11.1%) | ||
Diagnosis | 1 | 60 (100%) | 0 | 0 | 60 (24.7%) | V=1.00 (p<0.001) |
2 | 0 | 89 (100%) | 0 | 89 (36.6%) | ||
3 | 0 | 0 | 94 (100%) | 94 (38.7%) | ||
Diabetes | 0 | 22 (36.7%) | 69 (77.5%) | 74 (78.7%) | 165 (67.9%) | V=0.38 (p<0.001) |
1 | 38 (63.3%) | 20 (22.5%) | 20 (21.3%) | 78 (32.1%) | ||
Hipertension | 0 | 16 (28.6%) | 47 (54.7%) | 58 (63.7%) | 121 (51.9%) | V=0.27 (p<0.001) |
1 | 40 (71.4%) | 39 (45.3%) | 33 (36.3%) | 112 (48.1%) | ||
Hiperlipidemia | 0 | 38 (67.9%) | 73 (84.9%) | 89 (97.8%) | 200 (85.8%) | V=0.33 (p<0.001) |
1 | 18 (32.1%) | 13 (15.1%) | 2 (2.2%) | 33 (14.2%) | ||
Smoking | 0 | 43 (72.9%) | 36 (40.4%) | 51 (58.6%) | 130 (55.3%) | V=0.26 (p<0.001) |
1 | 16 (27.1%) | 53 (59.6%) | 36 (41.4%) | 105 (44.7%) | ||
Alcohol_Consume | 0 | 52 (88.1%) | 39 (43.8%) | 79 (90.8%) | 170 (72.3%) | V=0.50 (p<0.001) |
1 | 7 (11.9%) | 50 (56.2%) | 8 (9.2%) | 65 (27.7%) | ||
BMI | μ ±DS | 30.82 ±5.15 | 26.28 ±4.02 | 26.12 ±5.04 | 27.38 ±5.1 | Kruskal-Wallis: p<0.001 |
M (min:max) | 30.46 (18.48:42.17) | 25.97 (18.63:38.74) | 25.31 (16.02:46.02) | 26.44 (16.02:46.02) | ||
Encephalopathy (according to Child-Pugh score) | 1 | 55 (94.8%) | 82 (92.1%) | 84 (96.6%) | 221 (94.4%) | V=0.11 (p=0.265) |
2 | 2 (3.4%) | 7 (7.9%) | 3 (3.4%) | 12 (5.1%) | ||
3 | 1 (1.7%) | 0 | 0 | 1 (0.4%) | ||
Ascites (according to Child-Pugh score) | 1 | 48 (84.2%) | 67 (75.3%) | 76 (87.4%) | 191 (82.0%) | V=0.14 (p=0.048) |
2 | 8 (14.0%) | 12 (13.5%) | 9 (10.3%) | 29 (12.4%) | ||
3 | 1 (1.8%) | 10 (11.2%) | 2 (2.3%) | 13 (5.6%) | ||
Bilirubin total (µmol/L) | μ ±DS | 23.49 ±17.5 | 27.14 ±35.8 | 16.34 ±11.0 | 22.17 ±25.1 | Kruskal-Wallis: p=0.011 |
M (min:max) | 18 (5:104) | 16 (3:286) | 13.5 (4:62) | 16 (3:286) | ||
INR | μ ±DS | 1.16 ±0.161 | 1.19 ±0.217 | 1.12 ±0.155 | 1.15 ±0.184 | Kruskal-Wallis: p=0.065 |
M (min:max) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | 1.09 (0.8:1.9) | 1.11 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 32.83 ±4.67 | 32.14 ±6.35 | 34.54 ±5.37 | 33.20 ±5.69 | Kruskal-Wallis: p=0.028 |
M (min:max) | 33.5 (24:42) | 33 (20:43) | 35 (22:44) | 34 (20:44) | ||
CHILD | 1 | 34 (63.0%) | 50 (56.2%) | 68 (77.3%) | 152 (65.8%) | V=0.15 (p=0.029) |
2 | 18 (33.3%) | 31 (34.8%) | 18 (20.5%) | 67 (29.0%) | ||
3 | 2 (3.7%) | 8 (9.0%) | 2 (2.3%) | 12 (5.2%) | ||
BCLC | 0 | 3 (5.0%) | 10 (11.2%) | 5 (5.3%) | 18 (7.4%) | V=0.14 (p=0.286) |
1 | 26 (43.3%) | 33 (37.1%) | 47 (50.0%) | 106 (43.6%) | ||
2 | 15 (25.0%) | 24 (27.0%) | 18 (19.1%) | 57 (23.5%) | ||
3 | 13 (21.7%) | 14 (15.7%) | 21 (22.3%) | 48 (19.8%) | ||
4 | 3 (5.0%) | 8 (9.0%) | 3 (3.2%) | 14 (5.8%) | ||
Resection | 0 | 47 (78.3%) | 71 (79.8%) | 73 (78.5%) | 191 (78.9%) | V=0.02 (p=0.970) |
1 | 13 (21.7%) | 18 (20.2%) | 20 (21.5%) | 51 (21.1%) | ||
Transplant | 0 | 57 (95.0%) | 80 (89.9%) | 77 (82.8%) | 214 (88.4%) | V=0.15 (p=0.061) |
1 | 3 (5.0%) | 9 (10.1%) | 16 (17.2%) | 28 (11.6%) | ||
TACE | 0 | 53 (88.3%) | 77 (86.5%) | 79 (84.9%) | 209 (86.4%) | V=0.04 (p=0.836) |
1 | 7 (11.7%) | 12 (13.5%) | 14 (15.1%) | 33 (13.6%) | ||
TAE | 0 | 55 (91.7%) | 84 (94.4%) | 89 (95.7%) | 228 (94.2%) | V=0.07 (p=0.578) |
1 | 5 (8.3%) | 5 (5.6%) | 4 (4.3%) | 14 (5.8%) | ||
RFA | 0 | 57 (96.6%) | 88 (98.9%) | 88 (94.6%) | 233 (96.7%) | V=0.10 (p=0.277) |
1 | 2 (3.4%) | 1 (1.1%) | 5 (5.4%) | 8 (3.3%) | ||
MWA | 0 | 48 (80.0%) | 76 (85.4%) | 76 (81.7%) | 200 (82.6%) | V=0.06 (p=0.665) |
1 | 12 (20.0%) | 13 (14.6%) | 17 (18.3%) | 42 (17.4%) | ||
SIRT | 0 | 59 (98.3%) | 87 (97.8%) | 89 (95.7%) | 235 (97.1%) | V=0.07 (p=0.574) |
1 | 1 (1.7%) | 2 (2.2%) | 4 (4.3%) | 7 (2.9%) | ||
Sistemic_therapy | 0 | 48 (80.0%) | 73 (82.0%) | 80 (86.0%) | 201 (83.1%) | V=0.07 (p=0.592) |
1 | 12 (20.0%) | 16 (18.0%) | 13 (14.0%) | 41 (16.9%) | ||
Curative_treatment | 0 | 33 (55.0%) | 61 (68.5%) | 57 (61.3%) | 151 (62.4%) | V=0.11 (p=0.237) |
1 | 27 (45.0%) | 28 (31.5%) | 36 (38.7%) | 91 (37.6%) | ||
Loco_regional_therapies | 0 | 48 (80.0%) | 70 (78.7%) | 74 (79.6%) | 192 (79.3%) | V=0.01 (p=0.978) |
1 | 12 (20.0%) | 19 (21.3%) | 19 (20.4%) | 50 (20.7%) | ||
No_treatment | 0 | 54 (90.0%) | 72 (80.9%) | 82 (88.2%) | 208 (86.0%) | V=0.11 (p=0.215) |
1 | 6 (10.0%) | 17 (19.1%) | 11 (11.8%) | 34 (14.0%) | ||
Treatment | Curative | 27 (45.0%) | 28 (31.5%) | 36 (38.7%) | 91 (37.6%) | V=0.14 (p=0.268) |
Transplant | 3 (5.0%) | 9 (10.1%) | 15 (16.1%) | 27 (11.2%) | ||
Loco-regional | 12 (20.0%) | 19 (21.3%) | 19 (20.4%) | 50 (20.7%) | ||
Sistemic | 12 (20.0%) | 16 (18.0%) | 12 (12.9%) | 40 (16.5%) | ||
No treatment | 6 (10.0%) | 17 (19.1%) | 11 (11.8%) | 34 (14.0%) | ||
Performance Status | 0 | 36 (62.1%) | 52 (58.4%) | 53 (58.9%) | 141 (59.5%) | V=0.10 (p=0.805) |
1 | 16 (27.6%) | 23 (25.8%) | 26 (28.9%) | 65 (27.4%) | ||
2 | 4 (6.9%) | 8 (9.0%) | 8 (8.9%) | 20 (8.4%) | ||
3 | 2 (3.4%) | 5 (5.6%) | 1 (1.1%) | 8 (3.4%) | ||
4 | 0 | 1 (1.1%) | 2 (2.2%) | 3 (1.3%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | ||||||
Factor | Detalis | ASH | VIRAL | Total | Statistics |
DG | 89 (48.6%) | 94 (51.4%) | 183 | ||
Gender | F | 11 (12.4%) | 23 (24.5%) | 34 (18.6%) | OR=0.44 [0.20, 0.96] (p=0.038) |
M | 78 (87.6%) | 71 (75.5%) | 149 (81.4%) | ||
Age | μ ±DS | 66.70 ±8.69 | 62.74 ±9.25 | 64.66 ±9.17 | T-test: p=0.003 |
M (min:max) | 66.7 (45.2:86) | 60.7 (45.5:83.9) | 65.2 (45.2:86) | ||
Year_of_diagnosis | 2008 | 1 (1.1%) | 1 (1.1%) | 2 (1.1%) | V=0.30 (p=0.118) |
2009 | 4 (4.5%) | 2 (2.1%) | 6 (3.3%) | ||
2010 | 8 (9.0%) | 8 (8.5%) | 16 (8.7%) | ||
2011 | 6 (6.7%) | 16 (17.0%) | 22 (12.0%) | ||
2012 | 7 (7.9%) | 8 (8.5%) | 15 (8.2%) | ||
2013 | 7 (7.9%) | 6 (6.4%) | 13 (7.1%) | ||
2014 | 5 (5.6%) | 10 (10.6%) | 15 (8.2%) | ||
2015 | 7 (7.9%) | 10 (10.6%) | 17 (9.3%) | ||
2016 | 11 (12.4%) | 13 (13.8%) | 24 (13.1%) | ||
2017 | 8 (9.0%) | 10 (10.6%) | 18 (9.8%) | ||
2018 | 12 (13.5%) | 8 (8.5%) | 20 (10.9%) | ||
2019 | 13 (14.6%) | 2 (2.1%) | 15 (8.2%) | ||
Survival | μ ±DS | 29.65 ±29.6 | 31.13 ±25.3 | 30.39 ±27.4 | MW: p=0.278 |
M (min:max) | 20 (0:114) | 23 (0:112) | 23 (0:114) | ||
MRI_diagnosis | 0 | 61 (68.5%) | 58 (62.4%) | 119 (65.4%) | OR=1.31 [0.71, 2.43] (p=0.437) |
1 | 28 (31.5%) | 35 (37.6%) | 63 (34.6%) | ||
CT_Diagnosis | 0 | 35 (39.3%) | 42 (45.2%) | 77 (42.3%) | OR=0.79 [0.44, 1.42] (p=0.456) |
1 | 54 (60.7%) | 51 (54.8%) | 105 (57.7%) | ||
US_Diagnosis | 0 | 60 (67.4%) | 62 (66.7%) | 122 (67.0%) | OR=1.03 [0.56, 1.92] (p=1.000) |
1 | 29 (32.6%) | 31 (33.3%) | 60 (33.0%) | ||
HCC_Screening_18months_before | 0 | 58 (65.2%) | 43 (45.7%) | 101 (55.2%) | OR=2.22 [1.22, 4.03] (p=0.011) |
1 | 31 (34.8%) | 51 (54.3%) | 82 (44.8%) | ||
US_Screening | 0 | 70 (78.7%) | 60 (63.8%) | 130 (71.0%) | OR=2.09 [1.08, 4.03] (p=0.034) |
1 | 19 (21.3%) | 34 (36.2%) | 53 (29.0%) | ||
MRI_Screening | 0 | 80 (89.9%) | 87 (92.6%) | 167 (91.3%) | OR=0.72 [0.25, 2.01] (p=0.605) |
1 | 9 (10.1%) | 7 (7.4%) | 16 (8.7%) | ||
CT_Screening | 0 | 71 (79.8%) | 76 (80.9%) | 147 (80.3%) | OR=0.93 [0.45, 1.94] (p=1.000) |
1 | 18 (20.2%) | 18 (19.1%) | 36 (19.7%) | ||
ASH | 0 | 0 | 94 (100%) | 94 (51.4%) | OR=0.00 [0.00, 0.00] (p<0.001) |
1 | 89 (100%) | 0 | 89 (48.6%) | ||
NASH | 0 | 89 (100%) | 94 (100%) | 183 (100%) | V=NaN (p=1.000) |
Cirrhosis | 80 (89.9%) | 77 (81.9%) | 157 (85.8%) | OR=1.96 [0.83, 4.67] (p=0.142) | |
HCV | 0 | 89 (100%) | 27 (28.7%) | 116 (63.4%) | OR=439.36 [26.33, 7 332.05] (p<0.001) |
1 | 0 | 67 (71.3%) | 67 (36.6%) | ||
HBc | 0 | 89 (100%) | 67 (71.3%) | 156 (85.2%) | OR=72.93 [4.37, 1 216.98] (p<0.001) |
1 | 0 | 27 (28.7%) | 27 (14.8%) | ||
Diagnosis | 2 | 89 (100%) | 0 | 89 (48.6%) | OR=Inf [664.18, Inf] (p<0.001) |
3 | 0 | 94 (100%) | 94 (51.4%) | ||
Diabetes | 0 | 69 (77.5%) | 74 (78.7%) | 143 (78.1%) | OR=0.93 [0.46, 1.88] (p=0.860) |
1 | 20 (22.5%) | 20 (21.3%) | 40 (21.9%) | ||
Hipertension | 0 | 47 (54.7%) | 58 (63.7%) | 105 (59.3%) | OR=0.69 [0.38, 1.25] (p=0.226) |
1 | 39 (45.3%) | 33 (36.3%) | 72 (40.7%) | ||
Hiperlipidemia | 0 | 73 (84.9%) | 89 (97.8%) | 162 (91.5%) | OR=0.13 [0.03, 0.58] (p=0.002) |
1 | 13 (15.1%) | 2 (2.2%) | 15 (8.5%) | ||
Smoking | 0 | 36 (40.4%) | 51 (58.6%) | 87 (49.4%) | OR=0.48 [0.26, 0.87] (p=0.023) |
1 | 53 (59.6%) | 36 (41.4%) | 89 (50.6%) | ||
Alcohol_Consume | 0 | 39 (43.8%) | 79 (90.8%) | 118 (67.0%) | OR=0.08 [0.03, 0.18] (p<0.001) |
1 | 50 (56.2%) | 8 (9.2%) | 58 (33.0%) | ||
BMI | μ ±DS | 26.28 ±4.02 | 26.12 ±5.04 | 26.20 ±4.53 | MW: p=0.541 |
M (min:max) | 25.97 (18.63:38.74) | 25.31 (16.02:46.02) | 25.75 (16.02:46.02) | ||
Encephalopathy (according to Child-Pugh score) | 1 | 82 (92.1%) | 84 (96.6%) | 166 (94.3%) | OR=0.42 [0.10, 1.67] (p=0.330) |
2 | 7 (7.9%) | 3 (3.4%) | 10 (5.7%) | ||
Ascites (according to Child-Pugh score) | 1 | 67 (75.3%) | 76 (87.4%) | 143 (81.2%) | V=0.19 (p=0.043) |
2 | 12 (13.5%) | 9 (10.3%) | 21 (11.9%) | ||
3 | 10 (11.2%) | 2 (2.3%) | 12 (6.8%) | ||
Bilirubin total (µmol/L) | μ ±DS | 27.14 ±35.8 | 16.34 ±11.0 | 21.77 ±27.0 | MW: p=0.017 |
M (min:max) | 16 (3:286) | 13.5 (4:62) | 15 (3:286) | ||
INR | μ ±DS | 1.19 ±0.217 | 1.12 ±0.155 | 1.15 ±0.191 | MW: p=0.033 |
M (min:max) | 1.11 (0.8:2.07) | 1.09 (0.8:1.9) | 1.1 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 32.14 ±6.35 | 34.54 ±5.37 | 33.32 ±6.0 | MW: p=0.017 |
M (min:max) | 33 (20:43) | 35 (22:44) | 34 (20:44) | ||
CHILD | 1 | 50 (56.2%) | 68 (77.3%) | 118 (66.7%) | V=0.24 (p=0.007) |
2 | 31 (34.8%) | 18 (20.5%) | 49 (27.7%) | ||
3 | 8 (9.0%) | 2 (2.3%) | 10 (5.6%) | ||
BCLC | 0 | 10 (11.2%) | 5 (5.3%) | 15 (8.2%) | V=0.22 (p=0.074) |
1 | 33 (37.1%) | 47 (50.0%) | 80 (43.7%) | ||
2 | 24 (27.0%) | 18 (19.1%) | 42 (23.0%) | ||
3 | 14 (15.7%) | 21 (22.3%) | 35 (19.1%) | ||
4 | 8 (9.0%) | 3 (3.2%) | 11 (6.0%) | ||
Resection | 0 | 71 (79.8%) | 73 (78.5%) | 144 (79.1%) | OR=1.08 [0.53, 2.21] (p=0.857) |
1 | 18 (20.2%) | 20 (21.5%) | 38 (20.9%) | ||
Transplant | 0 | 80 (89.9%) | 77 (82.8%) | 157 (86.3%) | OR=1.85 [0.77, 4.43] (p=0.199) |
1 | 9 (10.1%) | 16 (17.2%) | 25 (13.7%) | ||
TACE | 0 | 77 (86.5%) | 79 (84.9%) | 156 (85.7%) | OR=1.14 [0.49, 2.61] (p=0.834) |
1 | 12 (13.5%) | 14 (15.1%) | 26 (14.3%) | ||
TAE | 0 | 84 (94.4%) | 89 (95.7%) | 173 (95.1%) | OR=0.76 [0.20, 2.91] (p=0.743) |
1 | 5 (5.6%) | 4 (4.3%) | 9 (4.9%) | ||
RFA | 0 | 88 (98.9%) | 88 (94.6%) | 176 (96.7%) | OR=5.00 [0.57, 43.67] (p=0.212) |
1 | 1 (1.1%) | 5 (5.4%) | 6 (3.3%) | ||
MWA | 0 | 76 (85.4%) | 76 (81.7%) | 152 (83.5%) | OR=1.31 [0.59, 2.88] (p=0.553) |
1 | 13 (14.6%) | 17 (18.3%) | 30 (16.5%) | ||
SIRT | 0 | 87 (97.8%) | 89 (95.7%) | 176 (96.7%) | OR=1.96 [0.35, 10.95] (p=0.683) |
1 | 2 (2.2%) | 4 (4.3%) | 6 (3.3%) | ||
Sistemic_therapy | 0 | 73 (82.0%) | 80 (86.0%) | 153 (84.1%) | OR=0.74 [0.33, 1.65] (p=0.545) |
1 | 16 (18.0%) | 13 (14.0%) | 29 (15.9%) | ||
Curative_treatment | 0 | 61 (68.5%) | 57 (61.3%) | 118 (64.8%) | OR=1.38 [0.75, 2.54] (p=0.353) |
1 | 28 (31.5%) | 36 (38.7%) | 64 (35.2%) | ||
Loco_regional_therapies | 0 | 70 (78.7%) | 74 (79.6%) | 144 (79.1%) | OR=0.95 [0.46, 1.93] (p=1.000) |
1 | 19 (21.3%) | 19 (20.4%) | 38 (20.9%) | ||
No_treatment | 0 | 72 (80.9%) | 82 (88.2%) | 154 (84.6%) | OR=0.57 [0.25, 1.29] (p=0.219) |
1 | 17 (19.1%) | 11 (11.8%) | 28 (15.4%) | ||
Treatment | Curative | 28 (31.5%) | 36 (38.7%) | 64 (35.2%) | V=0.15 (p=0.371) |
Transplant | 9 (10.1%) | 15 (16.1%) | 24 (13.2%) | ||
Loco-regional | 19 (21.3%) | 19 (20.4%) | 38 (20.9%) | ||
Sistemic | 16 (18.0%) | 12 (12.9%) | 28 (15.4%) | ||
No treatment | 17 (19.1%) | 11 (11.8%) | 28 (15.4%) | ||
Performance Status | 0 | 52 (58.4%) | 53 (58.9%) | 105 (58.7%) | V=0.13 (p=0.527) |
1 | 23 (25.8%) | 26 (28.9%) | 49 (27.4%) | ||
2 | 8 (9.0%) | 8 (8.9%) | 16 (8.9%) | ||
3 | 5 (5.6%) | 1 (1.1%) | 6 (3.4%) | ||
4 | 1 (1.1%) | 2 (2.2%) | 3 (1.7%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Factor | Detalis | NASH | VIRAL | Total | Statistics |
DG | 60 (39.0%) | 94 (61.0%) | 154 | ||
Gender | F | 10 (16.7%) | 23 (24.5%) | 33 (21.4%) | OR=0.62 [0.27, 1.41] (p=0.315) |
M | 50 (83.3%) | 71 (75.5%) | 121 (78.6%) | ||
Age | μ ±DS | 70.24 ±7.04 | 62.74 ±9.25 | 65.66 ±9.19 | Welch: p<0.001 |
M (min:max) | 70.45 (50.9:86.1) | 60.7 (45.5:83.9) | 66.2 (45.5:86.1) | ||
Year_of_diagnosis | 2008 | 1 (1.7%) | 1 (1.1%) | 2 (1.3%) | V=0.29 (p=0.317) |
2009 | 2 (3.3%) | 2 (2.1%) | 4 (2.6%) | ||
2010 | 5 (8.3%) | 8 (8.5%) | 13 (8.4%) | ||
2011 | 3 (5.0%) | 16 (17.0%) | 19 (12.3%) | ||
2012 | 6 (10.0%) | 8 (8.5%) | 14 (9.1%) | ||
2013 | 3 (5.0%) | 6 (6.4%) | 9 (5.8%) | ||
2014 | 5 (8.3%) | 10 (10.6%) | 15 (9.7%) | ||
2015 | 6 (10.0%) | 10 (10.6%) | 16 (10.4%) | ||
2016 | 7 (11.7%) | 13 (13.8%) | 20 (13.0%) | ||
2017 | 7 (11.7%) | 10 (10.6%) | 17 (11.0%) | ||
2018 | 7 (11.7%) | 8 (8.5%) | 15 (9.7%) | ||
2019 | 8 (13.3%) | 2 (2.1%) | 10 (6.5%) | ||
Survival | μ ±DS | 25.05 ±26.0 | 31.13 ±25.3 | 28.67 ±25.7 | MW: p=0.049 |
M (min:max) | 15 (0:110) | 23 (0:112) | 21 (0:112) | ||
MRI_diagnosis | 0 | 40 (66.7%) | 58 (62.4%) | 98 (64.1%) | OR=1.21 [0.61, 2.39] (p=0.609) |
1 | 20 (33.3%) | 35 (37.6%) | 55 (35.9%) | ||
CT_Diagnosis | 0 | 24 (40.0%) | 42 (45.2%) | 66 (43.1%) | OR=0.81 [0.42, 1.56] (p=0.617) |
1 | 36 (60.0%) | 51 (54.8%) | 87 (56.9%) | ||
US_Diagnosis | 0 | 38 (63.3%) | 62 (66.7%) | 100 (65.4%) | OR=0.86 [0.44, 1.70] (p=0.729) |
1 | 22 (36.7%) | 31 (33.3%) | 53 (34.6%) | ||
HCC_Screening_18months_before | 0 | 33 (55.0%) | 43 (45.7%) | 76 (49.4%) | OR=1.45 [0.76, 2.78] (p=0.322) |
1 | 27 (45.0%) | 51 (54.3%) | 78 (50.6%) | ||
US_Screening | 0 | 41 (68.3%) | 60 (63.8%) | 101 (65.6%) | OR=1.22 [0.61, 2.43] (p=0.605) |
1 | 19 (31.7%) | 34 (36.2%) | 53 (34.4%) | ||
MRI_Screening | 0 | 54 (90.0%) | 87 (92.6%) | 141 (91.6%) | OR=0.72 [0.23, 2.27] (p=0.569) |
1 | 6 (10.0%) | 7 (7.4%) | 13 (8.4%) | ||
CT_Screening | 0 | 50 (83.3%) | 76 (80.9%) | 126 (81.8%) | OR=1.18 [0.51, 2.77] (p=0.831) |
1 | 10 (16.7%) | 18 (19.1%) | 28 (18.2%) | ||
ASH | 0 | 60 (100%) | 94 (100%) | 154 (100%) | V=NaN (p=1.000) |
NASH | 0 | 0 | 94 (100%) | 94 (61.0%) | OR=0.00 [0.00, 0.00] (p<0.001) |
1 | 60 (100%) | 0 | 60 (39.0%) | ||
Cirrhosis | 47 (78.3%) | 77 (81.9%) | 124 (80.5%) | OR=0.80 [0.36, 1.79] (p=0.677) | |
HCV | 0 | 60 (100%) | 27 (28.7%) | 87 (56.5%) | OR=297.00 [17.73, 4 974.44] (p<0.001) |
1 | 0 | 67 (71.3%) | 67 (43.5%) | ||
HBc | 0 | 60 (100%) | 67 (71.3%) | 127 (82.5%) | OR=49.30 [2.94, 825.66] (p<0.001) |
1 | 0 | 27 (28.7%) | 27 (17.5%) | ||
Diagnosis | 1 | 60 (100%) | 0 | 60 (39.0%) | OR=Inf [447.80, Inf] (p<0.001) |
3 | 0 | 94 (100%) | 94 (61.0%) | ||
Diabetes | 0 | 22 (36.7%) | 74 (78.7%) | 96 (62.3%) | OR=0.16 [0.08, 0.32] (p<0.001) |
1 | 38 (63.3%) | 20 (21.3%) | 58 (37.7%) | ||
Hipertension | 0 | 16 (28.6%) | 58 (63.7%) | 74 (50.3%) | OR=0.23 [0.11, 0.47] (p<0.001) |
1 | 40 (71.4%) | 33 (36.3%) | 73 (49.7%) | ||
Hiperlipidemia | 0 | 38 (67.9%) | 89 (97.8%) | 127 (86.4%) | OR=0.05 [0.01, 0.21] (p<0.001) |
1 | 18 (32.1%) | 2 (2.2%) | 20 (13.6%) | ||
Smoking | 0 | 43 (72.9%) | 51 (58.6%) | 94 (64.4%) | OR=1.90 [0.93, 3.88] (p=0.082) |
1 | 16 (27.1%) | 36 (41.4%) | 52 (35.6%) | ||
Alcohol_Consume | 0 | 52 (88.1%) | 79 (90.8%) | 131 (89.7%) | OR=0.75 [0.26, 2.20] (p=0.593) |
1 | 7 (11.9%) | 8 (9.2%) | 15 (10.3%) | ||
BMI | μ ±DS | 30.82 ±5.15 | 26.12 ±5.04 | 28.06 ±5.57 | MW: p<0.001 |
M (min:max) | 30.46 (18.48:42.17) | 25.31 (16.02:46.02) | 26.86 (16.02:46.02) | ||
Encephalopathy (according to Child-Pugh score) | 1 | 55 (94.8%) | 84 (96.6%) | 139 (95.9%) | V=0.10 (p=0.470) |
2 | 2 (3.4%) | 3 (3.4%) | 5 (3.4%) | ||
3 | 1 (1.7%) | 0 | 1 (0.7%) | ||
Ascites (according to Child-Pugh score) | 1 | 48 (84.2%) | 76 (87.4%) | 124 (86.1%) | V=0.06 (p=0.784) |
2 | 8 (14.0%) | 9 (10.3%) | 17 (11.8%) | ||
3 | 1 (1.8%) | 2 (2.3%) | 3 (2.1%) | ||
Bilirubin total (µmol/L) | μ ±DS | 23.49 ±17.5 | 16.34 ±11.0 | 19.06 ±14.2 | MW: p=0.007 |
M (min:max) | 18 (5:104) | 13.5 (4:62) | 15 (4:104) | ||
INR | μ ±DS | 1.16 ±0.161 | 1.12 ±0.155 | 1.13 ±0.158 | MW: p=0.081 |
M (min:max) | 1.14 (0.99:1.78) | 1.09 (0.8:1.9) | 1.11 (0.8:1.9) | ||
Albumin (g/L) | μ ±DS | 32.83 ±4.67 | 34.54 ±5.37 | 33.85 ±5.15 | MW: p=0.034 |
M (min:max) | 33.5 (24:42) | 35 (22:44) | 34 (22:44) | ||
CHILD | 1 | 34 (63.0%) | 68 (77.3%) | 102 (71.8%) | V=0.15 (p=0.184) |
2 | 18 (33.3%) | 18 (20.5%) | 36 (25.4%) | ||
3 | 2 (3.7%) | 2 (2.3%) | 4 (2.8%) | ||
BCLC | 0 | 3 (5.0%) | 5 (5.3%) | 8 (5.2%) | V=0.09 (p=0.870) |
1 | 26 (43.3%) | 47 (50.0%) | 73 (47.4%) | ||
2 | 15 (25.0%) | 18 (19.1%) | 33 (21.4%) | ||
3 | 13 (21.7%) | 21 (22.3%) | 34 (22.1%) | ||
4 | 3 (5.0%) | 3 (3.2%) | 6 (3.9%) | ||
Resection | 0 | 47 (78.3%) | 73 (78.5%) | 120 (78.4%) | OR=0.99 [0.45, 2.18] (p=1.000) |
1 | 13 (21.7%) | 20 (21.5%) | 33 (21.6%) | ||
Transplant | 0 | 57 (95.0%) | 77 (82.8%) | 134 (87.6%) | OR=3.95 [1.10, 14.20] (p=0.026) |
1 | 3 (5.0%) | 16 (17.2%) | 19 (12.4%) | ||
TACE | 0 | 53 (88.3%) | 79 (84.9%) | 132 (86.3%) | OR=1.34 [0.51, 3.55] (p=0.636) |
1 | 7 (11.7%) | 14 (15.1%) | 21 (13.7%) | ||
TAE | 0 | 55 (91.7%) | 89 (95.7%) | 144 (94.1%) | OR=0.49 [0.13, 1.92] (p=0.315) |
1 | 5 (8.3%) | 4 (4.3%) | 9 (5.9%) | ||
RFA | 0 | 57 (96.6%) | 88 (94.6%) | 145 (95.4%) | OR=1.62 [0.30, 8.63] (p=0.706) |
1 | 2 (3.4%) | 5 (5.4%) | 7 (4.6%) | ||
MWA | 0 | 48 (80.0%) | 76 (81.7%) | 124 (81.0%) | OR=0.89 [0.39, 2.04] (p=0.834) |
1 | 12 (20.0%) | 17 (18.3%) | 29 (19.0%) | ||
SIRT | 0 | 59 (98.3%) | 89 (95.7%) | 148 (96.7%) | OR=2.65 [0.29, 24.31] (p=0.649) |
1 | 1 (1.7%) | 4 (4.3%) | 5 (3.3%) | ||
Sistemic_therapy | 0 | 48 (80.0%) | 80 (86.0%) | 128 (83.7%) | OR=0.65 [0.27, 1.54] (p=0.373) |
1 | 12 (20.0%) | 13 (14.0%) | 25 (16.3%) | ||
Curative_treatment | 0 | 33 (55.0%) | 57 (61.3%) | 90 (58.8%) | OR=0.77 [0.40, 1.49] (p=0.502) |
1 | 27 (45.0%) | 36 (38.7%) | 63 (41.2%) | ||
Loco_regional_therapies | 0 | 48 (80.0%) | 74 (79.6%) | 122 (79.7%) | OR=1.03 [0.46, 2.31] (p=1.000) |
1 | 12 (20.0%) | 19 (20.4%) | 31 (20.3%) | ||
No_treatment | 0 | 54 (90.0%) | 82 (88.2%) | 136 (88.9%) | OR=1.21 [0.42, 3.46] (p=0.798) |
1 | 6 (10.0%) | 11 (11.8%) | 17 (11.1%) | ||
Treatment | Curative | 27 (45.0%) | 36 (38.7%) | 63 (41.2%) | V=0.19 (p=0.242) |
Transplant | 3 (5.0%) | 15 (16.1%) | 18 (11.8%) | ||
Loco-regional | 12 (20.0%) | 19 (20.4%) | 31 (20.3%) | ||
Sistemic | 12 (20.0%) | 12 (12.9%) | 24 (15.7%) | ||
No treatment | 6 (10.0%) | 11 (11.8%) | 17 (11.1%) | ||
Performance Status | 0 | 36 (62.1%) | 53 (58.9%) | 89 (60.1%) | V=0.13 (p=0.646) |
1 | 16 (27.6%) | 26 (28.9%) | 42 (28.4%) | ||
2 | 4 (6.9%) | 8 (8.9%) | 12 (8.1%) | ||
3 | 2 (3.4%) | 1 (1.1%) | 3 (2.0%) | ||
4 | 0 | 2 (2.2%) | 2 (1.4%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Factor | Detalis | NASH | ASH | Total | Statistics |
DG | 60 (40.3%) | 89 (59.7%) | 149 | ||
Gender | F | 10 (16.7%) | 11 (12.4%) | 21 (14.1%) | OR=1.42 [0.56, 3.58] (p=0.480) |
M | 50 (83.3%) | 78 (87.6%) | 128 (85.9%) | ||
Age | μ ±DS | 70.24 ±7.04 | 66.70 ±8.69 | 68.12 ±8.22 | MW: p=0.018 |
M (min:max) | 70.45 (50.9:86.1) | 66.7 (45.2:86) | 68.3 (45.2:86.1) | ||
Year_of_diagnosis | 2008 | 1 (1.7%) | 1 (1.1%) | 2 (1.3%) | V=0.12 (p=0.998) |
2009 | 2 (3.3%) | 4 (4.5%) | 6 (4.0%) | ||
2010 | 5 (8.3%) | 8 (9.0%) | 13 (8.7%) | ||
2011 | 3 (5.0%) | 6 (6.7%) | 9 (6.0%) | ||
2012 | 6 (10.0%) | 7 (7.9%) | 13 (8.7%) | ||
2013 | 3 (5.0%) | 7 (7.9%) | 10 (6.7%) | ||
2014 | 5 (8.3%) | 5 (5.6%) | 10 (6.7%) | ||
2015 | 6 (10.0%) | 7 (7.9%) | 13 (8.7%) | ||
2016 | 7 (11.7%) | 11 (12.4%) | 18 (12.1%) | ||
2017 | 7 (11.7%) | 8 (9.0%) | 15 (10.1%) | ||
2018 | 7 (11.7%) | 12 (13.5%) | 19 (12.8%) | ||
2019 | 8 (13.3%) | 13 (14.6%) | 21 (14.1%) | ||
Survival | μ ±DS | 25.05 ±26.0 | 29.65 ±29.6 | 27.78 ±28.2 | MW: p=0.594 |
M (min:max) | 15 (0:110) | 20 (0:114) | 17 (0:114) | ||
MRI_diagnosis | 0 | 40 (66.7%) | 61 (68.5%) | 101 (67.8%) | OR=0.92 [0.46, 1.85] (p=0.859) |
1 | 20 (33.3%) | 28 (31.5%) | 48 (32.2%) | ||
CT_Diagnosis | 0 | 24 (40.0%) | 35 (39.3%) | 59 (39.6%) | OR=1.03 [0.53, 2.01] (p=1.000) |
1 | 36 (60.0%) | 54 (60.7%) | 90 (60.4%) | ||
US_Diagnosis | 0 | 38 (63.3%) | 60 (67.4%) | 98 (65.8%) | OR=0.83 [0.42, 1.66] (p=0.725) |
1 | 22 (36.7%) | 29 (32.6%) | 51 (34.2%) | ||
HCC_Screening_18months_before | 0 | 33 (55.0%) | 58 (65.2%) | 91 (61.1%) | OR=0.65 [0.33, 1.28] (p=0.234) |
1 | 27 (45.0%) | 31 (34.8%) | 58 (38.9%) | ||
US_Screening | 0 | 41 (68.3%) | 70 (78.7%) | 111 (74.5%) | OR=0.59 [0.28, 1.23] (p=0.182) |
1 | 19 (31.7%) | 19 (21.3%) | 38 (25.5%) | ||
MRI_Screening | 0 | 54 (90.0%) | 80 (89.9%) | 134 (89.9%) | OR=1.01 [0.34, 3.01] (p=1.000) |
1 | 6 (10.0%) | 9 (10.1%) | 15 (10.1%) | ||
CT_Screening | 0 | 50 (83.3%) | 71 (79.8%) | 121 (81.2%) | OR=1.27 [0.54, 2.98] (p=0.672) |
1 | 10 (16.7%) | 18 (20.2%) | 28 (18.8%) | ||
ASH | 0 | 60 (100%) | 0 | 60 (40.3%) | OR=Inf [423.98, Inf] (p<0.001) |
1 | 0 | 89 (100%) | 89 (59.7%) | ||
NASH | 0 | 0 | 89 (100%) | 89 (59.7%) | OR=0.00 [0.00, 0.00] (p<0.001) |
1 | 60 (100%) | 0 | 60 (40.3%) | ||
Cirrhosis | 47 (78.3%) | 80 (89.9%) | 127 (85.2%) | OR=0.41 [0.16, 1.02] (p=0.062) | |
HCV | 0 | 60 (100%) | 89 (100%) | 149 (100%) | V=NaN (p=1.000) |
HBc | 0 | 60 (100%) | 89 (100%) | 149 (100%) | V=NaN (p=1.000) |
Diagnosis | 1 | 60 (100%) | 0 | 60 (40.3%) | OR=Inf [423.98, Inf] (p<0.001) |
2 | 0 | 89 (100%) | 89 (59.7%) | ||
Diabetes | 0 | 22 (36.7%) | 69 (77.5%) | 91 (61.1%) | OR=0.17 [0.08, 0.35] (p<0.001) |
1 | 38 (63.3%) | 20 (22.5%) | 58 (38.9%) | ||
Hipertension | 0 | 16 (28.6%) | 47 (54.7%) | 63 (44.4%) | OR=0.33 [0.16, 0.68] (p=0.003) |
1 | 40 (71.4%) | 39 (45.3%) | 79 (55.6%) | ||
Hiperlipidemia | 0 | 38 (67.9%) | 73 (84.9%) | 111 (78.2%) | OR=0.38 [0.17, 0.85] (p=0.022) |
1 | 18 (32.1%) | 13 (15.1%) | 31 (21.8%) | ||
Smoking | 0 | 43 (72.9%) | 36 (40.4%) | 79 (53.4%) | OR=3.96 [1.94, 8.07] (p<0.001) |
1 | 16 (27.1%) | 53 (59.6%) | 69 (46.6%) | ||
Alcohol_Consume | 0 | 52 (88.1%) | 39 (43.8%) | 91 (61.5%) | OR=9.52 [3.90, 23.27] (p<0.001) |
1 | 7 (11.9%) | 50 (56.2%) | 57 (38.5%) | ||
BMI | μ ±DS | 30.82 ±5.15 | 26.28 ±4.02 | 28.09 ±5.01 | MW: p<0.001 |
M (min:max) | 30.46 (18.48:42.17) | 25.97 (18.63:38.74) | 27.05 (18.48:42.17) | ||
Encephalopathy (according to Child-Pugh score) | 1 | 55 (94.8%) | 82 (92.1%) | 137 (93.2%) | V=0.14 (p=0.262) |
2 | 2 (3.4%) | 7 (7.9%) | 9 (6.1%) | ||
3 | 1 (1.7%) | 0 | 1 (0.7%) | ||
Ascites (according to Child-Pugh score) | 1 | 48 (84.2%) | 67 (75.3%) | 115 (78.8%) | V=0.18 (p=0.105) |
2 | 8 (14.0%) | 12 (13.5%) | 20 (13.7%) | ||
3 | 1 (1.8%) | 10 (11.2%) | 11 (7.5%) | ||
Bilirubin total (µmol/L) | μ ±DS | 23.49 ±17.5 | 27.14 ±35.8 | 25.76 ±30.2 | MW: p=0.659 |
M (min:max) | 18 (5:104) | 16 (3:286) | 17 (3:286) | ||
INR | μ ±DS | 1.16 ±0.161 | 1.19 ±0.217 | 1.18 ±0.197 | MW: p=0.615 |
M (min:max) | 1.14 (0.99:1.78) | 1.11 (0.8:2.07) | 1.13 (0.8:2.07) | ||
Albumin (g/L) | μ ±DS | 32.83 ±4.67 | 32.14 ±6.35 | 32.41 ±5.74 | MW: p=0.616 |
M (min:max) | 33.5 (24:42) | 33 (20:43) | 33 (20:43) | ||
CHILD | 1 | 34 (63.0%) | 50 (56.2%) | 84 (58.7%) | V=0.11 (p=0.443) |
2 | 18 (33.3%) | 31 (34.8%) | 49 (34.3%) | ||
3 | 2 (3.7%) | 8 (9.0%) | 10 (7.0%) | ||
BCLC | 0 | 3 (5.0%) | 10 (11.2%) | 13 (8.7%) | V=0.15 (p=0.482) |
1 | 26 (43.3%) | 33 (37.1%) | 59 (39.6%) | ||
2 | 15 (25.0%) | 24 (27.0%) | 39 (26.2%) | ||
3 | 13 (21.7%) | 14 (15.7%) | 27 (18.1%) | ||
4 | 3 (5.0%) | 8 (9.0%) | 11 (7.4%) | ||
Resection | 0 | 47 (78.3%) | 71 (79.8%) | 118 (79.2%) | OR=0.92 [0.41, 2.05] (p=0.840) |
1 | 13 (21.7%) | 18 (20.2%) | 31 (20.8%) | ||
Transplant | 0 | 57 (95.0%) | 80 (89.9%) | 137 (91.9%) | OR=2.14 [0.55, 8.25] (p=0.362) |
1 | 3 (5.0%) | 9 (10.1%) | 12 (8.1%) | ||
TACE | 0 | 53 (88.3%) | 77 (86.5%) | 130 (87.2%) | OR=1.18 [0.44, 3.19] (p=0.807) |
1 | 7 (11.7%) | 12 (13.5%) | 19 (12.8%) | ||
TAE | 0 | 55 (91.7%) | 84 (94.4%) | 139 (93.3%) | OR=0.65 [0.18, 2.37] (p=0.524) |
1 | 5 (8.3%) | 5 (5.6%) | 10 (6.7%) | ||
RFA | 0 | 57 (96.6%) | 88 (98.9%) | 145 (98.0%) | OR=0.32 [0.03, 3.65] (p=0.564) |
1 | 2 (3.4%) | 1 (1.1%) | 3 (2.0%) | ||
MWA | 0 | 48 (80.0%) | 76 (85.4%) | 124 (83.2%) | OR=0.68 [0.29, 1.62] (p=0.503) |
1 | 12 (20.0%) | 13 (14.6%) | 25 (16.8%) | ||
SIRT | 0 | 59 (98.3%) | 87 (97.8%) | 146 (98.0%) | OR=1.36 [0.12, 15.30] (p=1.000) |
1 | 1 (1.7%) | 2 (2.2%) | 3 (2.0%) | ||
Sistemic_therapy | 0 | 48 (80.0%) | 73 (82.0%) | 121 (81.2%) | OR=0.88 [0.38, 2.02] (p=0.832) |
1 | 12 (20.0%) | 16 (18.0%) | 28 (18.8%) | ||
Curative_treatment | 0 | 33 (55.0%) | 61 (68.5%) | 94 (63.1%) | OR=0.56 [0.28, 1.10] (p=0.119) |
1 | 27 (45.0%) | 28 (31.5%) | 55 (36.9%) | ||
Loco_regional_therapies | 0 | 48 (80.0%) | 70 (78.7%) | 118 (79.2%) | OR=1.09 [0.48, 2.44] (p=1.000) |
1 | 12 (20.0%) | 19 (21.3%) | 31 (20.8%) | ||
No_treatment | 0 | 54 (90.0%) | 72 (80.9%) | 126 (84.6%) | OR=2.13 [0.79, 5.75] (p=0.167) |
1 | 6 (10.0%) | 17 (19.1%) | 23 (15.4%) | ||
Treatment | Curative | 27 (45.0%) | 28 (31.5%) | 55 (36.9%) | V=0.18 (p=0.290) |
Transplant | 3 (5.0%) | 9 (10.1%) | 12 (8.1%) | ||
Loco-regional | 12 (20.0%) | 19 (21.3%) | 31 (20.8%) | ||
Sistemic | 12 (20.0%) | 16 (18.0%) | 28 (18.8%) | ||
No treatment | 6 (10.0%) | 17 (19.1%) | 23 (15.4%) | ||
Performance Status | 0 | 36 (62.1%) | 52 (58.4%) | 88 (59.9%) | V=0.09 (p=0.860) |
1 | 16 (27.6%) | 23 (25.8%) | 39 (26.5%) | ||
2 | 4 (6.9%) | 8 (9.0%) | 12 (8.2%) | ||
3 | 2 (3.4%) | 5 (5.6%) | 7 (4.8%) | ||
4 | 0 | 1 (1.1%) | 1 (0.7%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
1 References
- R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.